Lori J Goldstein Selected Research

Lori J Goldstein Research Topics

Disease

59	Breast Neoplasms (Breast Cancer) 01/2022 - 08/2002
33	Neoplasms (Cancer) 01/2022 - 08/2002
4	Triple Negative Breast Neoplasms 11/2021 - 11/2011
3	Neoplasm Metastasis (Metastasis) 01/2020 - 08/2015
2	Diarrhea 01/2018 - 07/2008
2	Fatigue 01/2018 - 07/2008
2	Exanthema (Rash) 01/2018 - 07/2008
2	Nausea 12/2014 - 07/2008
2	Carcinoma (Carcinomatosis) 11/2012 - 11/2006
1	Disease Progression 01/2022
1	Premature Menopause 01/2019
1	Hemorrhage 01/2018
1	Hyperglycemia 01/2018
1	Hypertension (High Blood Pressure) 01/2018
1	Pneumonia (Pneumonitis) 01/2018
1	Proteinuria 01/2018
1	Stomatitis 01/2018
1	Thrombosis (Thrombus) 01/2018
1	Hypertriglyceridemia 01/2018
1	Anemia 01/2018
1	Ductal Carcinoma 08/2015
1	Adenocarcinoma 08/2015
1	Genomic Instability 06/2015
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 02/2015
1	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 02/2015
1	Asthenia 12/2014
1	Fibrosis (Cirrhosis) 09/2011
1	Leukemia 08/2011
1	Noninfiltrating Intraductal Carcinoma (DCIS) 09/2009

Drug/Important Bio-Agent (IBA)

21	Hormones (Hormone)IBA 01/2022 - 08/2002
11	Estrogen ReceptorsIBA 08/2021 - 03/2003
8	Paclitaxel (Taxol)FDA LinkGeneric 11/2021 - 03/2003
7	Doxorubicin (Adriamycin)FDA LinkGeneric 11/2011 - 03/2003
6	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2019 - 03/2003
6	AnthracyclinesIBA 01/2018 - 11/2006
5	Progesterone Receptors (Progesterone Receptor)IBA 01/2019 - 07/2008
5	Tamoxifen FDA LinkGeneric 01/2017 - 08/2002
4	reparixinIBA 11/2021 - 09/2017
4	ErbB Receptors (EGF Receptor)IBA 01/2018 - 10/2007
4	Biomarkers (Surrogate Marker)IBA 01/2017 - 09/2009
3	human ERBB2 proteinIBA 12/2021 - 12/2009
3	Aromatase InhibitorsIBA 01/2018 - 08/2002
3	Biological ProductsIBA 03/2014 - 01/2010
3	RNA (Ribonucleic Acid)IBA 07/2012 - 12/2009
3	Docetaxel (Taxotere)FDA Link 09/2008 - 04/2003
2	Capecitabine (Xeloda)FDA Link 10/2021 - 01/2020
2	Gemcitabine FDA Link 10/2021 - 06/2015
2	eribulin FDA Link 10/2021 - 01/2020
2	Hematoxylin (Haematoxylon)IBA 08/2021 - 09/2015
2	Eosine Yellowish-(YS) (Eosin)IBA 08/2021 - 09/2015
2	Trastuzumab (Herceptin)FDA Link 01/2019 - 09/2017
2	Goserelin (Zoladex)FDA Link 01/2019 - 01/2015
2	Estrogens (Estrogen)FDA Link 01/2018 - 07/2008
2	taxaneIBA 01/2018 - 12/2014
2	Letrozole (Femara)FDA LinkGeneric 01/2017 - 07/2008
2	Carboplatin (JM8)FDA LinkGeneric 08/2015 - 06/2015
2	Pharmaceutical PreparationsIBA 12/2014 - 07/2008
2	Taxoids (Taxanes)IBA 12/2014 - 04/2003
1	Epidermal Growth Factor (EGF)IBA 01/2022
1	tetrachloroisophthalonitrile (Bravo)IBA 10/2021
1	niraparibIBA 10/2021
1	Vinorelbine (Navelbine)FDA LinkGeneric 10/2021
1	CollagenIBA 08/2021
1	neratinibIBA 01/2019
1	Bevacizumab (Avastin)FDA Link 01/2018
1	Fulvestrant (Faslodex)FDA Link 01/2018
1	abemaciclibIBA 01/2018
1	Everolimus FDA Link 01/2018
1	TOR Serine-Threonine KinasesIBA 01/2018
1	Chemokine ReceptorsIBA 09/2017
1	Vorinostat FDA Link 09/2017
1	Messenger RNA (mRNA)IBA 01/2017
1	Thyroid Nuclear Factor 1IBA 08/2015
1	Pemetrexed (MTA)FDA Link 08/2015
1	iniparibIBA 06/2015
1	Gonadotropin-Releasing Hormone (GnRH)FDA Link 01/2015
1	Alanine Transaminase (SGPT)IBA 12/2014
1	TrabectedinIBA 12/2014
1	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 11/2011
1	Dasatinib (BMS 354825)FDA Link 11/2011
1	src-Family KinasesIBA 11/2011
1	Dihydrotachysterol (AT 10)IBA 09/2011
1	ParaffinIBA 08/2011
1	Formaldehyde (Formol)FDA Link 08/2011
1	Proteins (Proteins, Gene)FDA Link 08/2011
1	AntibodiesIBA 08/2011
1	Lapatinib (GW572016)FDA Link 07/2008

Therapy/Procedure

36	Therapeutics 01/2022 - 08/2002
22	Drug Therapy (Chemotherapy) 12/2021 - 04/2006
12	Adjuvant Chemotherapy 10/2021 - 03/2003
9	Radiotherapy 01/2022 - 06/2007
4	Aftercare (After-Treatment) 09/2017 - 01/2005
3	Biological Therapy 03/2016 - 04/2014
2	Combination Drug Therapy (Combination Chemotherapy) 01/2017 - 01/2004
2	Neoadjuvant Therapy 08/2015 - 06/2015
2	Segmental Mastectomy (Lumpectomy) 08/2015 - 06/2007
2	Mastectomy (Mammectomy) 01/2012 - 09/2003
1	Treatment Delay 02/2019
1	Patient Transfer (Patient Dumping) 02/2014
1	Contraindications 11/2006